Protein detail
MGA
Maltase-glucoamylase (Alpha-1,4-glucosidase) (EC 3.2.1.20)
Protein symbol MGA | UniProt ID | EVMP score 0.38 |
Frequency | Transmembrane count 1 | Protein classification EnzymesFDA approved drug targetsMetabolic proteinsPlasma proteinsPredicted membrane proteins |
Basic Information
Protein Names
Maltase-glucoamylase (Alpha-1,4-glucosidase) (EC 3.2.1.20)
Protein Class
EnzymesFDA approved drug targetsMetabolic proteinsPlasma proteinsPredicted membrane proteins
Protein Function
- Enzymes
- FDA approved drug targets:Small molecule drugs
- ENZYME proteins:Hydrolases
Transmembrane
14..34; Helical; Signal-anchor for type II membrane protein
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Synonym
MGA
Gene Description
Maltase-glucoamylase
Chromosome
7
Position
141907813-142106747
EVMP Score
0.38
Fluorescence & Localization
Cell SpecificColonocytesSingle-Nuclei Brain Specificendothelial cell
Function & Pathway
Protein Function
- Enzymes
- FDA approved drug targets:Small molecule drugs
- ENZYME proteins:Hydrolases
Cellular Component
Molecular Function
Biological Process
KEGG
Reactome
Mediation Categories
Clinical-translation mediationFusion and delivery mediationImmune mediation
Relations & Evidence
Enzyme-Mediated Modification
0 records.
Ligand-Receptor Signaling
23 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | OmniPath | No | Yes | No | No | No |
| intracellular | intracellular | LOCATE | No | No | No | No | No |
| intracellular | intracellular | ComPPI | No | No | No | No | No |
| intracellular | intracellular | GO_Intercell | No | No | No | No | No |
| intracellular | intracellular | OmniPath | No | No | No | No | No |
| transmembrane | transmembrane | UniProt_location | No | No | No | No | No |
| transmembrane | transmembrane | UniProt_topology | No | No | No | No | No |
| transmembrane | transmembrane | UniProt_keyword | No | No | No | No | No |
| transmembrane_predicted | transmembrane | OmniPath | No | No | No | No | No |
| transmembrane | transmembrane | TopDB | No | No | No | No | No |
Page 1 of 3Next
Regulatory Interaction Network
0 records.
Protein Complex Composition
Isolation & Detection Technology
Sequence, Structure & Domains
Sequences
Length
2,753
Mass
312,022
Sequence
MARKKLKKFTTLEIVLSVLLLVLFIISIVLIVLLAKESLKSTAPDPGTTGTPDPGTTGTPDPGTTGTTHARTTGPPDPGTTGTTPVSAECPVVNELERINCIPDQPPTKATCDQRGCCWNPQGAVSVPWCYYSKNHSYHVEGNLVNTNAGFTARLKNLPSSPVFGSNVDNVLLTAEYQTSNRFHFKLTDQTNNRFEVPHEHVQSFSGNAAASLTYQVEISRQPFSIKVTRRSNNRVLFDSSIGPLLFADQFLQLSTRLPSTNVYGLGEHVHQQYRHDMNWKTWPIFNRDTTPNGNGTNLYGAQTFFLCLEDASGLSFGVFLMNSNAMEVVLQPAPAITYRTIGGILDFYVFLGNTPEQVVQEYLELIGRPALPSYWALGFHLSRYEYGTLDNMREVVERNRAAQLPYDVQHADIDYMDERRDFTYDSVDFKGFPEFVNELHNNGQKLVIIVDPAISNNSSSSKPYGPYDRGSDMKIWVNSSDGVTPLIGEVWPGQTVFPDYTNPNCAVWWTKEFELFHNQVEFDGIWIDMNEVSNFVDGSVSGCSTNNLNNPPFTPRILDGYLFCKTLCMDAVQHWGKQYDIHNLYGYSMAVATAEAAKTVFPNKRSFILTRSTFAGSGKFAAHWLGDNTATWDDLRWSIPGVLEFNLFGIPMVGPDICGFALDTPEELCRRWMQLGAFYPFSRNHNGQGYKDQDPASFGADSLLLNSSRHYLNIRYTLLPYLYTLFFRAHSRGDTVARPLLHEFYEDNSTWDVHQQFLWGPGLLITPVLDEGAEKVMAYVPDAVWYDYETGSQVRWRKQKVEMELPGDKIGLHLRGGYIFPTQQPNTTTLASRKNPLGLIIALDENKEAKGELFWDNGETKDTVANKVYLLCEFSVTQNRLEVNISQSTYKDPNNLAFNEIKILGTEEPSNVTVKHNGVPSQTSPTVTYDSNLKVAIITDIDLLLGEAYTVEWSIKIRDEEKIDCYPDENGASAENCTARGCIWEASNSSGVPFCYFVNDLYSVSDVQYNSHGATADISLKSSVYANAFPSTPVNPLRLDVTYHKNEMLQFKIYDPNKNRYEVPVPLNIPSMPSSTPEGQLYDVLIKKNPFGIEIRRKSTGTIIWDSQLLGFTFSDMFIRISTRLPSKYLYGFGETEHRSYRRDLEWHTWGMFSRDQPPGYKKNSYGVHPYYMGLEEDGSAHGVLLLNSNAMDVTFQPLPALTYRTTGGVLDFYVFLGPTPELVTQQYTELIGRPVMVPYWSLGFQLCRYGYQNDSEIASLYDEMVAAQIPYDVQYSDIDYMERQLDFTLSPKFAGFPALINRMKADGMRVILILDPAISGNETQPYPAFTRGVEDDVFIKYPNDGDIVWGKVWPDFPDVVVNGSLDWDSQVELYRAYVAFPDFFRNSTAKWWKREIEELYNNPQNPERSLKFDGMWIDMNEPSSFVNGAVSPGCRDASLNHPPYMPHLESRDRGLSSKTLCMESQQILPDGSLVQHYNVHNLYGWSQTRPTYEAVQEVTGQRGVVITRSTFPSSGRWAGHWLGDNTAAWDQLKKSIIGMMEFSLFGISYTGADICGFFQDAEYEMCVRWMQLGAFYPFSRNHNTIGTRRQDPVSWDAAFVNISRNVLQTRYTLLPYLYTLMQKAHTEGVTVVRPLLHEFVSDQVTWDIDSQFLLGPAFLVSPVLERNARNVTAYFPRARWYDYYTGVDINARGEWKTLPAPLDHINLHVRGGYILPWQEPALNTHLSRKNPLGLIIALDENKEAKGELFWDDGQTKDTVAKKVYLLCEFSVTQNHLEVTISQSTYKDPNNLAFNEIKILGMEEPSNVTVKHNGVPSQTSPTVTYDSNLKVAIITDINLFLGEAYTVEWSIKIRDEEKIDCYPDENGDSAENCTARGCIWEASNSSGVPFCYFVNDLYSVSDVQYNSHGATADISLKSSVHANAFPSTPVNPLRLDVTYHKNEMLQFKIYDPNNNRYEVPVPLNIPSVPSSTPEGQLYDVLIKKNPFGIEIRRKSTGTIIWDSQLLGFTFNDMFIRISTRLPSKYLYGFGETEHTSYRRDLEWHTWGMFSRDQPPGYKKNSYGVHPYYMGLEEDGSAHGVLLLNSNAMDVTFQPLPALTYRTTGGVLDFYVFLGPTPELVTQQYTELIGRPVMVPYWSLGFQLCRYGYQNDSEISSLYDEMVAAQIPYDVQYSDIDYMERQLDFTLSPKFAGFPALINRMKADGMRVILILDPAISGNETQPYPAFTRGVEDDVFIKYPNDGDIVWGKVWPDFPDVVVNGSLDWDSQVELYRAYVAFPDFFRNSTAKWWKREIEELYNNPQNPERSLKFDGMWIDMNEPSSFVNGAVSPGCRDASLNHPPYMPYLESRDRGLSSKTLCMESQQILPDGSPVQHYNVHNLYGWSQTRPTYEAVQEVTGQRGVVITRSTFPSSGRWAGHWLGDNTAAWDQLKKSIIGMMEFSLFGISYTGADICGFFQDAEYEMCVRWMQLGAFYPFSRNHNTIGTRRQDPVSWDVAFVNISRTVLQTRYTLLPYLYTLMHKAHTEGVTVVRPLLHEFVSDQVTWDIDSQFLLGPAFLVSPVLERNARNVTAYFPRARWYDYYTGVDINARGEWKTLPAPLDHINLHVRGGYILPWQEPALNTHLSRQKFMGFKIALDDEGTAGGWLFWDDGQSIDTYGKGLYYLASFSASQNTMQSHIIFNNYITGTNPLKLGYIEIWGVGSVPVTSVSISVSGMVITPSFNNDPTTQVLSIDVTDRNISLHNFTSLTWISTL
Alternative Products
Event=Alternative splicing; Named isoforms=2; Name=2; IsoId=O43451-2; Sequence=Displayed; Name=1; IsoId=O43451-1; Sequence=VSP_061364
Alternative Sequence
1594..2489; Missing (in isoform 1)
3D Structural Models
Turn
221..224; 231..233; 333..335; 427..432; 531..533; 548..550; 563..566; 761..763; 789..791; 862..868; 932..935; 1876..1878; 1974..1976; 1985..1988; 2095..2097; 2318..2320; 2335..2337; 2352..2356; 2541..2545; 2553..2555; 2581..2583; 2654..2656; 2741..2743
Helix
95..97; 109..115; 240..242; 356..367; 375..378; 390..402; 414..416; 433..442; 466..474; 504..518; 559..561; 579..582; 583..585; 586..601; 618..620; 633..648; 667..677; 696..699; 704..718; 720..732; 741..745; 749..751; 830..833; 1871..1875; 1920..1923; 2118..2129; 2137..2140; 2152..2165; 2176..2178; 2180..2182; 2189..2191; 2194..2203; 2225..2233; 2265..2271; 2284..2298; 2304..2306; 2349..2351; 2374..2377; 2378..2380; 2381..2397; 2412..2414; 2428..2443; 2461..2471; 2490..2492; 2495..2525; 2533..2535; 2622..2625; 2657..2659
Beta Strand
104..106; 129..131; 136..146; 148..157; 163..165; 169..179; 182..189; 214..220; 225..230; 236..239; 246..248; 251..257; 263..269; 272..276; 279..285; 303..309; 316..321; 327..332; 336..344; 346..355; 379..382; 409..412; 417..420; 446..451; 461..463; 483..486; 489..491; 494..497; 524..528; 536..540; 609..613; 623..625; 630..632; 653..655; 661..663; 680..685; 689..691; 737..739; 758..760; 764..767; 775..781; 786..788; 799..805; 812..816; 819..824; 838..843; 850..856; 859..861; 871..877; 879..889; 898..906; 911..917; 927..931; 936..941; 950..954; 1879..1881; 1891..1896; 1898..1901; 1908..1918; 1926..1928; 1932..1940; 1942..1951; 1953..1955; 1979..1984; 1989..1994; 2000..2003; 2010..2012; 2015..2021; 2023..2025; 2031..2033; 2036..2039; 2043..2050; 2068..2072; 2074..2076; 2078..2083; 2087..2094; 2098..2106; 2108..2113; 2141..2144; 2171..2174; 2207..2212; 2240..2242; 2247..2253; 2273..2277; 2311..2315; 2323..2330; 2363..2365; 2367..2369; 2371..2373; 2403..2407; 2417..2419; 2424..2426; 2447..2449; 2455..2457; 2474..2476; 2483..2485; 2529..2531; 2548..2552; 2556..2559; 2563..2565; 2568..2573; 2578..2580; 2590..2597; 2604..2608; 2610..2616; 2630..2635; 2642..2648; 2651..2653; 2663..2669; 2674..2683; 2686..2688; 2691..2698; 2711..2717; 2725..2727
3D Structure
X-ray crystallography (12)
Domain & Motif Annotations
Compositional Bias
44..85; Low complexity
Domain (CC)
The N-terminal maltase domain (ntMGAM) mainly hydrolyzes short length oligomaltoses having two to four glucose residues.; DOMAIN: The C-terminal glucoamylase domain (ctMGAM) acts on longer maltoside substrates having four to seven glucose residues.
Domain (FT)
88..134; P-type 1; 954..1000; P-type 2; 1850..1896; P-type 3
Region
41..87; Disordered; 356..737; Maltase; 1221..1632; Glucoamylase
Protein Families
Glycosyl hydrolase 31 family
Sequence Similarities
Belongs to the glycosyl hydrolase 31 family.
Clinical Relevance
Disease Involvement
FDA approved drug targets
Related Diseases
Biomarker
Approved; Investigative; Phase 3; Phase 1/2; Phase 2
Drug Targets
FDA approved drug targets
Drugs
Antibody